📊 PHIO Key Takeaways
Is Phio Pharmaceuticals Corp. (PHIO) a Good Investment?
Phio operates as an early-stage pharmaceutical company with minimal revenue ($231K) while burning $8M annually in operating cash flow, creating significant execution risk despite improving loss metrics YoY. With approximately 2.5 years of cash runway at current burn rates, the company must demonstrate near-term revenue acceleration or cost reduction to achieve profitability before capital depletion.
Why Buy Phio Pharmaceuticals Corp. Stock? PHIO Key Strengths
- Exceptional balance sheet strength with $21M cash, zero long-term debt, and $1.3M total liabilities
- Outstanding liquidity position with 17.81x current ratio providing substantial operational flexibility
- Improving loss trajectory with net loss declining 21.7% YoY and EPS improving 80.6% YoY
PHIO Stock Risks: Phio Pharmaceuticals Corp. Investment Risks
- Deeply unprofitable operations with operating margin of -3991.3% and net margin of -3765.4% indicating massive operational losses
- Negative operating cash flow of -$8M annually with revenue of only $231K suggesting pre-commercial or failed commercialization stage
- Limited cash runway of approximately 2.5 years at current burn rate with unproven path to profitability or financing capability
Key Metrics to Watch
- Revenue growth trajectory and timeline to commercial product revenue generation
- Operating cash burn rate and trend in cash consumption relative to clinical milestones
- Monthly cash burn rate reduction and achievement of non-dilutive funding sources
Phio Pharmaceuticals Corp. (PHIO) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 17.81x current ratio provides a solid financial cushion.
PHIO Profit Margin, ROE & Profitability Analysis
PHIO vs Healthcare Sector: How Phio Pharmaceuticals Corp. Compares
How Phio Pharmaceuticals Corp. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Phio Pharmaceuticals Corp. Stock Overvalued? PHIO Valuation Analysis 2026
Based on fundamental analysis, Phio Pharmaceuticals Corp. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Phio Pharmaceuticals Corp. Balance Sheet: PHIO Debt, Cash & Liquidity
PHIO Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Phio Pharmaceuticals Corp.'s revenue has declined by 38% over the 5-year period, indicating business contraction. The most recent EPS of $-46.76 indicates the company is currently unprofitable.
PHIO Revenue Growth, EPS Growth & YoY Performance
PHIO Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2020 | N/A | -$1.7M | N/A |
| Q2 2020 | N/A | -$1.7M | N/A |
| Q1 2020 | N/A | -$2.1M | N/A |
| Q3 2019 | N/A | -$1.5M | N/A |
| Q2 2019 | N/A | -$1.9M | N/A |
| Q1 2019 | $21.0K | -$2.1M | N/A |
| Q3 2018 | N/A | -$1.5M | N/A |
| Q2 2018 | N/A | -$1.9M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Phio Pharmaceuticals Corp. Dividends, Buybacks & Capital Allocation
PHIO SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Phio Pharmaceuticals Corp. (CIK: 0001533040)
📋 Recent SEC Filings
❓ Frequently Asked Questions about PHIO
What is the AI rating for PHIO?
Phio Pharmaceuticals Corp. (PHIO) has an AI rating of SELL with 65% confidence, based on fundamental analysis of SEC EDGAR filings.
What are PHIO's key strengths?
Claude: Exceptional balance sheet strength with $21M cash, zero long-term debt, and $1.3M total liabilities. Outstanding liquidity position with 17.81x current ratio providing substantial operational flexibility.
What are the risks of investing in PHIO?
Claude: Deeply unprofitable operations with operating margin of -3991.3% and net margin of -3765.4% indicating massive operational losses. Negative operating cash flow of -$8M annually with revenue of only $231K suggesting pre-commercial or failed commercialization stage.
What is PHIO's revenue and growth?
Phio Pharmaceuticals Corp. reported revenue of $231.0K.
Does PHIO pay dividends?
Phio Pharmaceuticals Corp. does not currently pay dividends.
Where can I find PHIO SEC filings?
Official SEC filings for Phio Pharmaceuticals Corp. (CIK: 0001533040) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is PHIO's EPS?
Phio Pharmaceuticals Corp. has a diluted EPS of $-0.86.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is PHIO a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Phio Pharmaceuticals Corp. has a SELL rating with 65% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is PHIO stock overvalued or undervalued?
Valuation metrics for PHIO: ROE of -43.2% (sector avg: 15%), net margin of -3,765.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy PHIO stock in 2026?
Our dual AI analysis gives Phio Pharmaceuticals Corp. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is PHIO's free cash flow?
Phio Pharmaceuticals Corp.'s operating cash flow is $-8.0M, with capital expenditures of $12.0K. FCF margin is -3,459.3%.
How does PHIO compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -3,765.4% (avg: 12%), ROE -43.2% (avg: 15%), current ratio 17.81 (avg: 2).